Evidence map›Paper›PMID 37700758›Full record

ReviewFuture virology2023

Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy.

Mona Fani, Maryam Moossavi, Hasan Bakhshi, Abozar Nasiri Jahrodi, Mohammad Reza Khazdair, Amir Hossein Zardast, Shokouh Ghafari

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mona FaniVector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.ORCID https://orcid.org/0000-0001-9396-3890
Maryam MoossaviDepartment of Immunology, Birjand University of Medical Sciences, Birjand, Iran.
Hasan BakhshiVector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.ORCID https://orcid.org/0000-0002-8819-4561
Abozar Nasiri JahrodiNorth Khorasan University of Medical Sciences, Bojnurd, Iran.ORCID https://orcid.org/0000-0002-5777-2154
Mohammad Reza KhazdairPharmaceutical Science & Clinical Physiology, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.ORCID https://orcid.org/0000-0001-9854-6121
Amir Hossein ZardastMashhad University of Medical Sciences, Mashhad, Iran.
Shokouh GhafariCellular & Molecular Research Center, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, 8815713471, Iran.ORCID https://orcid.org/0000-0002-8747-8693
North Khorasan University of Medical Sciences · IRBirjand University of Medical Sciences · IRMashhad University of Medical Sciences · IRShahrekord University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite passing the pandemic phase of the COVID-19, researchers are still investigating various drugs. Previous evidence suggests that blocking the calcium channels may be a suitable treatment option. Ca

Indexed as

calcium channel blockerCOVID-19SARS-CoV-2viroporins

Identifiers

PMID37700758
PMCPMC10494978
OpenAlexW4386603146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.